Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment
NCT02873650
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
5
Enrollment
INDUSTRY
Sponsor class
Stopped
Study was terminated due to continued enrolment difficulties.
Conditions
Hepatic Impairment
Interventions
DRUG:
dabrafenib
Sponsor
Novartis Pharmaceuticals